EQL Stock Overview
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EQL Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr43.80 |
| 52 Week High | kr46.00 |
| 52 Week Low | kr24.70 |
| Beta | 0.70 |
| 1 Month Change | 1.62% |
| 3 Month Change | 22.69% |
| 1 Year Change | 28.45% |
| 3 Year Change | 16.80% |
| 5 Year Change | 251.81% |
| Change since IPO | 655.17% |
Recent News & Updates
Recent updates
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Shareholder Returns
| EQL | SE Healthcare | SE Market | |
|---|---|---|---|
| 7D | 0.9% | 6.0% | 1.7% |
| 1Y | 28.4% | 16.4% | 14.7% |
Return vs Industry: EQL exceeded the Swedish Healthcare industry which returned 17.6% over the past year.
Return vs Market: EQL exceeded the Swedish Market which returned 14.1% over the past year.
Price Volatility
| EQL volatility | |
|---|---|
| EQL Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 5.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: EQL has not had significant price volatility in the past 3 months.
Volatility Over Time: EQL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 19 | Axel Schorling | www.eqlpharma.com |
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
EQL Pharma AB (publ) Fundamentals Summary
| EQL fundamental statistics | |
|---|---|
| Market cap | kr1.27b |
| Earnings (TTM) | kr22.14m |
| Revenue (TTM) | kr246.37m |
57.5x
P/E Ratio5.2x
P/S RatioIs EQL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EQL income statement (TTM) | |
|---|---|
| Revenue | kr246.37m |
| Cost of Revenue | kr134.68m |
| Gross Profit | kr111.69m |
| Other Expenses | kr89.55m |
| Earnings | kr22.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 0.76 |
| Gross Margin | 45.33% |
| Net Profit Margin | 8.98% |
| Debt/Equity Ratio | 56.7% |
How did EQL perform over the long term?
See historical performance and comparison